Citations

Showing 10 of 108083 citations.

Elderly patients with glomerular diseases and IgA nephropathy
Lin, Jing , Cheng, Zhen , Qian, Qi , Cheng, Zhen

Mayo Clinic

Nephrology | November 20, 2017 | Volume: 22 | Issue: S4 | Pages: 20-26

10.1111/nep.13144 | PMID 29155502 Get It

Summary at a GlanceAs the population ages, large numbers of elderly patients will present with kidney diseases. Kidney biopsy for elderly patients is generally well tolerated and informative. Compared with younger adults, IgA nephropathy in the elderly carries a poor prognosis. In patients with intercurrent infections, IgA‐dominant postinfectious GN should be carefully differentiated from idiopathic IgA nephropathy. Existing ESRD and mortality prediction models/scoring systems for IgA nephropathy may not be generalized to elderly patients.
Brick and mortar IMT core lab goes automated and online
Naqvi, Tasneem Z.

Mayo Clinic

European Journal of Preventive Cardiology | November 20, 2017 | Volume: 25 | Issue: 2 | Pages: 150-153

10.1177/2047487317743045 | PMID 29154682 Get It

Cerebrovascular Reactivity and Vascular Activation in Postmenopausal Women With Histories of Preeclampsia
Barnes, Jill N. , Harvey, Ronée E. , Miller, Kathleen B. , Jayachandran, Muthuvel , Malterer, Katherine R., Lahr, Brian D. , Bailey, Kent R. , Joyner, Michael J. , Miller, Virginia M. , Barnes, J N , Harvey, Ronée E , Joyner, Michael J

Mayo Clinic

Hypertension | November 20, 2017 | Volume: 71 | Issue: 1 | Pages: 110-117

10.1161/hypertensionaha.117.10248 | PMID 29158356 Get It

Cerebrovascular reactivity (CVR) is reduced in patients with cognitive decline. Women with a history of preeclampsia are at increased risk for cognitive decline. This study examined an association between pregnancy history and CVR using a subgroup of 40 age- and parity-matched pairs of women having histories of preeclampsia (n=27) or normotensive pregnancy (n=29) and the association of activated blood elements with CVR. Middle cerebral artery velocity was measured by Doppler ultrasound before and during hypercapnia to assess CVR. Thirty-eight parameters of blood cellular elements, microvesicles, and cell–cell interactions measured in venous blood were assessed for association with CVR using principal component analysis. Middle cerebral artery velocity was lower in the preeclampsia compared with the normotensive group at baseline (63±4 versus 73±3 cm/s; P =0.047) and during hypercapnia ( P =0.013–0.056). CVR was significantly lower in the preeclampsia compared with the normotensive group (2.1±1.3 versus 2.9±1.1 cm·s·mm Hg; P =0.009). Globally, the association of the 7 identified principal components with preeclampsia ( P =0.107) and with baseline middle cerebral artery velocity ( P =0.067) did not reach statistical significance. The interaction between pregnancy history and principal components with respect to CVR ( P =0.084) was driven by a nominally significant interaction between preeclampsia and the individual principal component defined by blood elements, platelet aggregation, and interactions of platelets with monocytes and granulocytes ( P =0.008). These results suggest that having a history of preeclampsia negatively affects the cerebral circulation years beyond the pregnancy and that this effect was associated with activated blood elements.
Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management
Shosha, Eslam , Pittock, Sean J. , Weinshenker, Brian G. , Flanagan, Eoin , Pittock, S J , Weinshenker, Brian G , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | November 20, 2017 | Volume: 23 | Issue: 14 | Pages: 1808-1817

10.1177/1352458517740215 | PMID 29154728 Get It

Neuromyelitis optica spectrum disorders (NMOSD) predominantly affect women who are of childbearing age. Understanding the interactions between pregnancy and NMOSD is important for clinical management. Aquaporin-4 (AQP4), the most common target antigen in NMOSD, is expressed on placenta in early pregnancy. A variety of immune and cytokine changes in pregnancy may impact pregnancy outcomes in NMOSD patients. Relapses continue during pregnancy and increase in frequency postpartum. Preeclampsia and fetal loss are more frequent in NMOSD than in controls. Transfer of AQP4-immunoglobulin G (IgG) from mother to baby occurs but appears not to cause disease. Several treatment options are relatively safe and mitigate the risk of relapse during pregnancy and postpartum. For patients with active NMOSD, it may be advisable to continue immunotherapy during pregnancy.
Syringe lubricant and adverse reactions
Wambier, Carlos Gustavo , Ostroski, Tayza Katelline Danilau , Wambier, Sarah Perillo de Farias , Beltrame, Flávio Luís , Cappel, Mark A., Piñeiro‐Maceira, Juan , Wambier, Carlos G , Cappel, Mark A.

Mayo Clinic

International Journal of Dermatology | November 20, 2017 | Volume: 57 | Issue: 1 | Pages: 122-123

10.1111/ijd.13825 | PMID 29152724 Get It

Brain functional connectivity in headache disorders: A narrative review of MRI investigations
Chong, Catherine D. , Hougaard, Anders , Schwedt, Todd J. , Chong, Catherine D

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | November 20, 2017 | Volume: 39 | Issue: 4 | Pages: 650-669

10.1177/0271678x17740794 | PMID 29154684 Get It

Resting-state functional magnetic resonance imaging (rs-fMRI) is used to interrogate the functional connectivity and network organization amongst brain regions. Functional connectivity is determined by measuring the extent of synchronization in the spontaneous fluctuations of blood oxygenation level dependent (BOLD) signal. Here, we review current rs-fMRI studies in headache disorders including migraine, trigeminal autonomic cephalalgias, and medication overuse headache. We discuss (1) brain network alterations that are shared amongst the different headache disorders and (2) network abnormalities distinct to each headache disorder. In order to focus the section on migraine, the headache disorder that has been most extensively studied, we chose to include articles that interrogated functional connectivity: (i) during the attack phase; (ii) in migraine patients with aura compared to migraine patients without aura; and (iii) of regions within limbic, sensory, motor, executive and default mode networks and those which participate in multisensory integration. The results of this review show that headache disorders are associated with atypical functional connectivity of regions associated with pain processing as well as atypical functional connectivity of multiple core resting state networks such as the salience, sensorimotor, executive, attention, limbic, visual, and default mode networks.
Nasoseptal flap closure of the eustachian tube for recalcitrant cerebrospinal fluid rhinorrhea
Patel, Vishal S. , Thamboo, Andrew , Hwang, Peter H. , Choby, Garret W, Choby, Garret , Blevins, Nikolas H. , Hwang, Peter H

Mayo Clinic

The Laryngoscope | November 20, 2017 | Volume: 128 | Issue: 7 | Pages: 1523-1526

10.1002/lary.26988 | PMID 29152752 Get It

Procedural trends, outcomes, and readmission rates pre‐and post‐FDA approval for MitraClip from the National Readmission Database (2013–14)
Panaich, Sidakpal , Arora, Shilpkumar , Badheka, Apurva, Kumar, Varun , Maor, Elad , Raphael, Claire E. , Deshmukh, Abhishek , Reeder, Guy S., Eleid, Mackram F. , Rihal, Charanjit S. , Panaich, Sidakpal S, Raphael, Claire , Eleid, Mackram F , Panaich, Sidakpal S , Maor, Elad , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 20, 2017 | Volume: 91 | Issue: 6 | Pages: 1171-1181

10.1002/ccd.27366 | PMID 29152829 Get It

AbstractBackgroundThere are sparse clinical data on the procedural trends, outcomes and readmission rates following FDA approval and expansion of Transcatheter mitral valve repair/MitraClip®. Whether a complex new technology can be disseminated safely and quickly is controversial.MethodsThe study cohort was derived from the National Readmission Data (NRD) 2013–14. MitraClip® was identified using appropriate International Classification of Diseases, 9th Revision, Clinical Modification (ICD‐9‐CM) codes. The primary outcome was a composite of in‐hospital mortality + procedural complications. Secondary outcome included 30‐day readmissions. Hierarchical two level logistic models were used to evaluate study outcomes.ResultsOur analysis included 2003 MitraClip® procedures. Overall in‐hospital mortality was 3.9%. As expected, there was a significant increase in procedural volume post‐FDA approval. Importantly, a corresponding downward trend in mortality and procedural complications was observed. Significant predictors of in‐hospital mortality and procedural complications included the use of vasopressors (P <0.001) and hemodynamic support (P < 0.001). Higher hospital volume (≥10 MitraClips/year) was associated with lower in‐hospital mortality and complications (P = 0.02). There were 304 (15.1%) 30‐day readmissions, with heart failure being the most common cause of readmission. Elective procedures had lower in‐hospital mortality (P < 0.001) and lower readmission rates (P = 0.011) compared with nonelective procedures.ConclusionA significant increase in MitraClip® procedural volumes occurred post‐FDA approval. Overall morbidity and mortality were low and trended downwards. Hospital procedure volume ≥10 cases were associated with lower mortality and overall complication rates. These data suggest a successful roll out of a very complex novel structural heart procedure.
Editorial Comment
Köhler, Tobias

Mayo Clinic

Journal of Urology | November 20, 2017 | Volume: 199 | Issue: 3 | Pages: 810-811

10.1016/j.juro.2017.10.047 | PMID 29154768 Get It

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Amstutz, Ursula , Henricks, Linda M. , Offer, Steven M. , Barbarino, Julia M., Schellens, Jan H.M. , Swen, Jesse J. , McLeod, Howard L. , Caudle, Kelly E. , Diasio, Robert B. , Schwab, Matthias , Lau‐Min, Kelsey S. , Klein, Teri E. , Offer, Steven M , Schwab, Matthias

Mayo Clinic

Clinical Pharmacology & Therapeutics | November 20, 2017 | Volume: 103 | Issue: 2 | Pages: 210-216

10.1002/cpt.911 | PMID 29152729 Get It

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase ( DPYD ) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5‐fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost‐effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/ ).